0001209191-15-022712.txt : 20150304 0001209191-15-022712.hdr.sgml : 20150304 20150304213951 ACCESSION NUMBER: 0001209191-15-022712 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150302 FILED AS OF DATE: 20150304 DATE AS OF CHANGE: 20150304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clovis Oncology, Inc. CENTRAL INDEX KEY: 0001466301 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 900475355 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: (303) 625-5000 MAIL ADDRESS: STREET 1: 2525 28TH STREET STREET 2: SUITE 100 CITY: BOULDER STATE: CO ZIP: 80301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MAST ERLE T CENTRAL INDEX KEY: 0001051411 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35347 FILM NUMBER: 15675610 MAIL ADDRESS: STREET 1: C/O SPIROS DEVELOPMENT CORP II INC STREET 2: 7475 LUSK BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-03-02 0 0001466301 Clovis Oncology, Inc. CLVS 0001051411 MAST ERLE T C/O CLOVIS ONCOLOGY, INC. 2525 28TH STREET, SUITE 100 BOULDER CO 80301 0 1 0 0 Executive VP and CFO Stock Option (right to buy) 79.05 2015-03-02 4 A 0 35000 0.00 A 2025-03-02 Common Stock 35000 35000 D The option shall vest as to 12.5% of the shares on March 2, 2016, and as to 37.5% of the shares in substantially equal installments over the 36 months immediately following such date. The option shall vest as to 25% of the shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib and the remaining 25% shall vest upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib. /s/ Erle T. Mast 2015-03-04